New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
07:08 EDTLGND, SPPISpectrum gains rights to Capitsol-enabled Melphalan
Spectrum Pharmaceuticals (SPPI) has gained global development and commercialization rights to Ligand Pharmaceuticalsí (LGND) Captisol-enabled, propylene glycol-free (PG-free) melphalan. Captisol-enabled melphalan is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum is assuming the responsibility for the ongoing pivotal clinical trial and will be responsible for filing an NDA, which is anticipated in the first half of 2014. Under the license agreement, Ligand will receive a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization.
News For SPPI;LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
10:00 EDTSPPIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:07 EDTSPPISpectrum initiated with a Hold at Jefferies
Subscribe for More Information
07:09 EDTSPPIJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 18, 2014
10:28 EDTLGNDLigand sees 2015 revenue $81M-$83M, consensus $91.87M
Three estimates make up consensus. Guidance issued in analyst day presentation slides.
10:27 EDTLGNDLigand sees 2017 EPS above $4.65, revenue above $146M
Subscribe for More Information
10:27 EDTLGNDLigand sees 2016 EPS above $3.20, revenue above $107M
Subscribe for More Information
10:25 EDTLGNDLigand guides 2015 EPS $2.14-$2.18, consensus $2.42
Subscribe for More Information
November 14, 2014
17:21 EDTLGNDLigand to host analyst day
Analyst Day to be held in New York on November 18 at 10 am. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use